Univercells Technologies

Univercells Technologies is a specialized provider of intensified biomanufacturing technologies, primarily serving the viral vector, vaccine, and cell and gene therapy (CGT) markets. Its core offerings include the scale-X™ family of fixed-bed bioreactors and the NevoLine™ upstream platform, which are designed to reduce costs, increase scalability, and simplify production processes for adherent cell culture. As a subsidiary of the industrial giant Donaldson, the company combines innovative bioprocess engineering with the commercial and manufacturing muscle of a larger corporation, positioning it to address critical bottlenecks in advanced therapy manufacturing.

Fixed-bed bioreactor systems (scale-X) and integrated upstream platforms (NevoLine) for intensified, scalable adherent cell culture, leveraging process intensification and chaining principles.

Univercells Technologies competes in the bioprocessing equipment market against major players like Cytiva, Sartorius, and Thermo Fisher Scientific, as well as other specialists in continuous processing and intensification. Its differentiation lies in its dedicated focus on fixed-bed technology for adherent cell culture, targeting a specific and critical bottleneck in viral production.